Tigecycline for the treatment of severe Clostridium difficile infection;Tigeciclina para el tratamiento de la infección severa por Clostridium difficile

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages 1005-1010

  Larson, Kelly C ^a   Belliveau, Paul P ^a   Spooner, Linda M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Clostridium difficile infection; Tigecycline

Indexed keywords

IMMUNOGLOBULIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG BILE LEVEL; DRUG PENETRATION; DRUG WITHDRAWAL; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LIVER DYSFUNCTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOSOCOMIAL PNEUMONIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEUS MIRABILIS BACTEREMIA; RECURRENT DISEASE; SEPTIC SHOCK; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; SEVERITY OF ILLNESS INDEX;

EID: 79960822735     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q080     Document Type: Article

References (21)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415.
2. Spencer RC. Clinical impact and associated costs of Clostridium difficile- associated disease. J Antimicrob Chemother 1998;41(suppl C): 5-12.
3. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
4. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449.
5. Luo RF, Banaei N. Is repeat PCR needed for diagnosis of Clostridium difficile infection? J Clin Microbiol 2010;48:3738-3741.
6. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-848.
7. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2009;48:425-429.
8. Product information. Tygacil (tigecycline). Philadelphia, PA: Wyeth Pharmaceuticals Inc., July 2010.
9. Norén T, Alriksson I, Åkerlund T, Burman LG, Unemo M. In vitro sus ceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 2010;16:1104-1110.
10. Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 2010;42:33-38.
11. Hawser S P. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents 2010;35:97-98.
12. Velissari D, Martsoukou M, Skarmoutsou N, et al. In vitro susceptibilities of toxigenic Clostridium difficile strains to 10 antimicrobial agents (abstract). Clin Microbiol Infect 2009;15:S391.
13. Hawser S P. Activity of tigecycline against multidrug-resistant clinical isolates of Clostridium spp. from Europe. Int J Antimicrob Agents 2010; 35:310-311.
14. 14C]tigecycline, a first-in class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007;35:1543-1553.
15. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006;50:3375-3380.
16. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48:1732-1735.
17. Lu CL, Liu CY, Liao CH, Huang YT, Wang HP, Hsueh PR. Severe and refractory Clostridium difficile infection successfully treated with tigecy-cline and metronidazole. Int J Antimicrob Agents 2010;35:311-312.
18. Cheong EYL, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust 2011;194:374-375.
19. Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010;38:755-758.
20. Koo HL, Garey KW, DuPont HL. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs 2010;19:825-836.
21. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-1918.